Immunovant Q4 FY2025 net loss $106.4M, cash $714M; new CEO Eric Venker

Immunovant, Inc.

2025-FY EPS reported -$2.73 vs consensus -$0.73 ▼ miss (-274.7%)

Net loss of $106.4M ($0.64/share) for Q4 FY2025, vs $75.3M ($0.52/share) a year ago.
Cash and equivalents $714M as of March 31, 2025; runway through GD readout expected in 2027.
Eric Venker, M.D. appointed CEO and Tiago Girao CFO in April 2025 as part of strategic transition.
R&D expenses $93.7M in Q4, up from $66.1M, driven by IMVT-1402 clinical trial costs.
Potentially registrational trials for IMVT-1402 in Sjögren's disease and second GD trial planned summer 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.